Arseus bond issue an extraordinary success
Offer to subscribe for bonds raises € 225 million and will be closed early
Waregem (Belgium) / Rotterdam (the Netherlands), 15 June 2012 - Arseus announces today that, in consultation with the Joint Lead Managers (ING Belgium, KBC Bank and BNP Paribas Fortis) and the Co-lead Manager (Belfius Bank), its public offering of bonds in Belgium and the Grand Duchy of Luxembourg has been closed after only the first day of the subscription period as the maximum amount of € 225 million has already been raised.
The total subscribed amount for the bond loan was significantly higher than the maximum targeted amount of € 225 million. The investors' subscriptions will therefore be reduced proportionally. Investors will be informed about this via their financial intermediaries. The bonds will be issued on 2 July 2012 and will be listed on the regulated market of NYSE Euronext Brussels.
The bonds have a term of 5 years and offer a fixed annual gross interest rate of 4.75%. The gross actuarial return on the issue price is 4.325%. The bonds will have a nominal value of € 1,000. The bonds are redeemable at 100% of the nominal value on 2 July 2017.
KBC Bank is acting as Global Coordinator for this bond issue. KBC Bank, ING Belgium and BNP Paribas Fortis are acting as Joint Lead Managers and Joint Bookrunners, with Belfius Bank acting as Co-lead Manager.
Further information on this public offering can be found in the prospectus issued by Arseus on 12 June 2012, as approved by the FSMA (Financial Services and Markets Authority). The prospectus is available from KBC Bank (www.kbc.be), ING Belgium (www.ing.be), BNP Paribas Fortis (www.bnpparibasfortis.be) and Belfius Bank (www.belfius.be), as well as on the Arseus website: www.arseus.com.
This press release was sent out by Arseus NV and Arseus BV.
For more information:
Constantijn van Rietschoten
Director of Corporate Communications
+31 88 33 11 222 (office)
+31 6 536 91 585 (mobile)
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in Europe, the US, Brazil and Argentina. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions.
The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
Please open the link below for the full press release: